Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Neumora Therapeutics, Inc. (NMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -18.53% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 165.19M USD | Price to earnings Ratio - | 1Y Target Price 7.04 |
Price to earnings Ratio - | 1Y Target Price 7.04 | ||
Volume (30-day avg) 1353075 | Beta - | 52 Weeks Range 0.90 - 17.19 | Updated Date 04/1/2025 |
52 Weeks Range 0.90 - 17.19 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Earnings Date
Report Date 2025-03-03 | When - | Estimate -0.4423 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.5% | Return on Equity (TTM) -64.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -142126288 | Price to Sales(TTM) - |
Enterprise Value -142126288 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 161979008 | Shares Floating 85270564 |
Shares Outstanding 161979008 | Shares Floating 85270564 | ||
Percent Insiders 27.52 | Percent Institutions 71.99 |
Analyst Ratings
Rating 4.33 | Target Price 15.54 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neumora Therapeutics, Inc.
Company Overview
History and Background
Neumora Therapeutics, Inc. is a biopharmaceutical company founded in 2019 focused on developing novel treatments for brain diseases. It went public in September 2023. The company aims to address unmet needs in neuropsychiatric disorders through precision medicine approaches.
Core Business Areas
- Neurology: Focuses on developing therapies for neurological disorders such as Parkinson's disease and Alzheimer's disease.
- Psychiatry: Dedicated to creating treatments for psychiatric illnesses like major depressive disorder and schizophrenia.
Leadership and Structure
The leadership team consists of Paul L. Berns (Chairman and CEO), along with other executives in research and development, clinical operations, and finance. The organizational structure is typical of a biopharmaceutical company, emphasizing research, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Navacaprant: A kappa opioid receptor (KOR) antagonist being developed for major depressive disorder (MDD). Phase 3 trials are ongoing. Competitors include companies developing novel antidepressants like Axsome Therapeutics with Auvelity.
- NMRA-266: A selective vasopressin 1A receptor (V1aR) antagonist in Phase 1 development for social anxiety disorder (SAD). No current market share data available. Competitors include companies with established anxiety treatments (SSRIs, SNRIs).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. There's a high unmet need for effective treatments in neuropsychiatric disorders, driving innovation.
Positioning
Neumora is positioned as a precision medicine company focused on novel targets in brain diseases. Its competitive advantage lies in its experienced management team and targeted approach to drug development.
Total Addressable Market (TAM)
The TAM for neuropsychiatric drugs is estimated to be in the tens of billions of dollars annually. Neumora's positioning within this market depends on the success of its pipeline products, particularly Navacaprant for MDD.
Upturn SWOT Analysis
Strengths
- Strong management team with experience in drug development
- Novel drug targets with potential for high efficacy
- Focus on precision medicine for neuropsychiatric disorders
- Strong financial backing from venture capital and IPO
Weaknesses
- Early-stage pipeline with high risk of failure
- Limited commercialization experience
- Dependence on successful clinical trial outcomes
- Relatively small company compared to established pharmaceutical giants
Opportunities
- Untapped market for effective treatments for neuropsychiatric disorders
- Potential for strategic partnerships with larger pharmaceutical companies
- Advancements in neuroscience and drug discovery technologies
- Favorable regulatory environment for innovative therapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Axsome Therapeutics, Inc. (AXSM)
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
- Acadia Pharmaceuticals Inc. (ACAD)
Competitive Landscape
Neumora is positioned as an innovative player with novel targets, but it faces competition from established companies with approved products and greater financial resources. Its success hinges on demonstrating superior efficacy and safety in clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A - Limited history as a public company.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals for its pipeline products. Analyst estimates are contingent on these milestones.
Recent Initiatives: Focus on advancing Navacaprant into Phase 3 clinical trials and progressing other pipeline candidates.
Summary
Neumora Therapeutics is a young, high-risk, high-reward biopharmaceutical company with a promising pipeline targeting unmet needs in neuropsychiatric disorders. Its success relies heavily on positive clinical trial results for its lead candidate. The company faces intense competition and regulatory hurdles. Navacaprant's success is crucial for future growth and shareholder value.
Similar Companies
ACAD
ACADIA Pharmaceuticals Inc
ACAD
ACADIA Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
AXSM
Axsome Therapeutics Inc
AXSM
Axsome Therapeutics Inc
BHVN
Biohaven Pharmaceutical Holding Co Ltd
BHVN
Biohaven Pharmaceutical Holding Co Ltd
Sources and Disclaimers
Data Sources:
- Neumora Therapeutics, Inc. Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market data is based on available information and may not be entirely accurate. Investment decisions should be made based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neumora Therapeutics, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2023-09-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.neumoratx.com |
Full time employees 110 | Website https://www.neumoratx.com | ||
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.